Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.
作者信息
Hearn Elizabeth B, Sherman Justin J
机构信息
University of Mississippi School of Pharmacy, Jackson, MS.
出版信息
Diabetes Spectr. 2021 Jan;34(1):73-75. doi: 10.2337/ds20-0033.
Abstract
摘要
相似文献
1
Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.
Diabetes Spectr. 2021 Jan;34(1):73-75. doi: 10.2337/ds20-0033.
2
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3.
3
[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Rev Med Liege. 2019 Sep;74(9):488-494.
4
Semaglutide as a promising antiobesity drug.
Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15.
5
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Adv Ther. 2019 Aug;36(8):2034-2051. doi: 10.1007/s12325-019-00965-y. Epub 2019 Jun 5.
6
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
Diabetes Ther. 2018 Aug;9(4):1533-1547. doi: 10.1007/s13300-018-0458-5. Epub 2018 Jun 15.
7
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):221-233. doi: 10.1080/14737167.2021.1860022. Epub 2021 Jan 12.
8
Semaglutide once-weekly: improved efficacy with a new safety warning.
Expert Rev Clin Pharmacol. 2018 Nov;11(11):1061-1072. doi: 10.1080/17512433.2018.1534201. Epub 2018 Oct 16.
9
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Diabetes Ther. 2019 Feb;10(1):159-176. doi: 10.1007/s13300-018-0542-x. Epub 2018 Dec 7.
10
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Adv Ther. 2020 Oct;37(10):4427-4445. doi: 10.1007/s12325-020-01464-1. Epub 2020 Aug 29.
引用本文的文献
1
A Closer Look at the Dermatological Profile of GLP-1 Agonists.
Diseases. 2025 Apr 22;13(5):127. doi: 10.3390/diseases13050127.
2
A Review of Glucagon-like Peptide-1 in Dermatology.
J Clin Aesthet Dermatol. 2025 Mar;18(3):42-50.
3
Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.
Clin Pharmacol Drug Dev. 2025 Apr;14(4):311-323. doi: 10.1002/cpdd.1514. Epub 2025 Jan 29.
4
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.
Medicina (Kaunas). 2024 Dec 26;61(1):17. doi: 10.3390/medicina61010017.
5
A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists.
Int J Womens Dermatol. 2024 Apr 5;10(2):e143. doi: 10.1097/JW9.0000000000000143. eCollection 2024 Jun.
6
Tirzepatide-Induced Injection Site Reaction.
Cureus. 2023 Sep 13;15(9):e45181. doi: 10.7759/cureus.45181. eCollection 2023 Sep.
本文引用的文献
1
10. Cardiovascular Disease and Risk Management: .
Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.
2
9. Pharmacologic Approaches to Glycemic Treatment: .
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
3
Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone.
JAAD Case Rep. 2018 Sep 18;4(8):830-832. doi: 10.1016/j.jdcr.2018.06.009. eCollection 2018 Sep.
4
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.
Diabetes Spectr. 2017 Aug;30(3):202-210. doi: 10.2337/ds16-0026.
5
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.
Patient Prefer Adherence. 2016 Jul 22;10:1299-307. doi: 10.2147/PPA.S106821. eCollection 2016.
6
Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Diabetes Spectr. 2015 Nov;28(4):283-8. doi: 10.2337/diaspect.28.4.283.
7
Adverse Effects of GLP-1 Receptor Agonists.
Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10.
8
Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.
Clin Ther. 2015 Aug;37(8):1813-21.e1. doi: 10.1016/j.clinthera.2015.05.505.
9
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Lancet. 2013 Jan 12;381(9861):117-24. doi: 10.1016/S0140-6736(12)61267-7. Epub 2012 Nov 7.
10
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981.
Zotero 插件